Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 533 results for "warner chilcott"

Actavis Says Warner Chilcott Unit Held Talks to Settle U.S. Probe

Reuters Health Information By Reuters Staff May18,2015 (Reuters) - Drug maker Actavis Plc said its Warner Chilcott unit held talks with U.S. government officials to discuss a potential resolution of an investigation into the unit's sales ... Diabetes Care, 1 month ago

10-Q - Warner Chilcott Ltd (0001620602) (Filer)

Document Format Files Seq Description Document Type Size 1 FORM 10-Q d912920d10q.htm 10-Q 1971337 2 EX-4.20 d912920dex420.htm EX-4.20 19505 3 EX-10.35 d912920dex1035.htm EX-10.35 67460 4 EX-10.36 d912920dex1036.htm EX-10.36 141133 5 EX-10.37 ...
 SEC1 month ago
Canadian Business Journal

Warner Chilcott Co., LLC v. Teva Pharms. USA, Inc.

Spring 2015 Case Name: , Civ. No. 11-6936 (FSH), 2015 U.S. Dist. LEXIS 26207 (D.N.J. Mar. 4, 2015) (Hochberg, J.) Drug Product and Patent(s)-in-Suit: Atelvia ® (risedronate / ethylene diamine tetraacetic acid); U.S. Pat. Nos. 7,645,459 ...
 JD Supra2 months ago Paratek Hires William Haskel as Senior Vice President, General Counsel and Corporate Secretary  BioSpace1 day ago Paratek Pharmaceuticals, Inc. Hires William Haskel As Senior Vice President, General Counsel And Corporate Secretary  FierceBiotech1 day ago Court Report - June 2015 #3  JD Supra1 week ago

Teva Launches Generic Actonel

Share this article: Teva announced the launch of Risedronate Sodium Tablets, the generic version of Warner Chilcott's Actonel . Actonel is a bisphosphonate indicated for the treatment and prevention of osteoporosis in postmenopausal ...
 Monthly Prescribing Reference1 month ago Teva Launches Generic Atelvia  Monthly Prescribing Reference1 month ago

Allergan Is Buying Its Way To Growth

at 18:54 PM EDT Growth through acquisitions is the name of the game for Allergan. Initially known as Watson Pharmaceutical, Allergan (AGN) has made a large number of buyouts, including a few multibillion-dollar deals in recent years, and has taken ...
 Marketplace7 hours ago

Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies

/PRNewswire/ -- Dermatological drugs - new study showing you trends, partnerships, and predicted revenues Where is the market for dermatological drugs heading? What are the commercial prospects for this market? Visiongain's new report shows you ...
 TickerTech.com3 days ago

FTC Amicus Brief Urges Appeals Court to Overturn District Court Decision that Pay-for-Delay Pharmaceutical Settlements Only Violate Antitrust Laws if Paid in Cash

The Federal Trade Commission filed an amicus brief in the U.S. Court of Appeals for the First Circuit urging the court to reject a district court decision in a reverse-payment patent settlement case holding that an alleged non-cash payment from a ...
 Federal Trade Commission1 week ago

Fitch: Allergan's Acquisition of Kythera Within Expectations; No Rating Actions

The acquisition of Kythera Biotherapeutics, Inc. (Kythera; NASDAQ: KYTH ) by Allergan plc (Allergan; NYSE: AGN ; f.k.a. Actavis plc) for approximately $2 billion is in line with expectations, according to Fitch Ratings. Fitch ...
 Crawford Financial Planning2 weeks ago FITCH : Allergan's Acquisition of Kythera Within Expectations; No Rating Actions  4 Traders2 weeks ago

Alert: Second Circuit Rules that "Product Hopping" May Constitute Unlawful Monopolization; Pharmaceutical Companies are Likely Targets of Future Antitrust Enforcement

Recent antitrust challenges to pharmaceutical companies' efforts to transition patients from drugs nearing the end of their patent life to next-generation drugs have increased the risk of pursuing such "product hopping" strategies. Pharmaceutical ...
 JD Supra2 weeks ago Second Circuit rules that "product hopping" may constitute unlawful monopolization; pharmaceutical companies are likely targets of future antitrust enforcement  Lexology2 weeks ago
Seeking Alpha

Foamix Is Going To Disrupt The $3 Billion Market For Acne, Buy It Now

Jun. 9, 2015 9:44 AM ET | About: Foamix Pharmaceuticals (FOMX), Includes: INSY, PFNX by: Christopher Stoehr Summary Phase II results of FMX101 in my opinion are better than any other approved acne treatment with no side effects. Topical ...
 Seeking Alpha3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - warner chilcott
Get updated on latest news & your favorite topics right in your inbox!
More     Less